Gestational diabetes mellitus (GDM) is a metabolic disease affecting an increasing number
of pregnant women around the world. It is not only associated with numerous perinatal …

Cognitive impairment in individuals with diabetes represents a multifaceted and increasingly
prevalent health concern. This review critically examines the current evidence regarding the …

Abstract Glucagon-like peptide-1 (GLP-1), secreted by L cells in the small intestine, assumes
a central role in managing type 2 diabetes mellitus (T2DM) and obesity. Its influence on …

Since we aim to test new options to find medication for cognitive disorders, we have begun
to assess the effect of semaglutide and to conduct a review gathering studies that have …

Background Glucagon‐like peptide‐1 receptor agonists are used increasingly in the
management of patients living with type 2 diabetes mellitus and obesity. In patients using …

La enfermedad renal diabética, frecuente en pacientes con diabetes mellitus tipo 2, se
asocia con un marcado incremento de la morbimortalidad, especialmente cardiovascular, y …

Our previous studies showed that microinjection into the median eminence of the sheep of
glucagon-like peptide-1 (GLP-1) or its receptor agonist exendin-4 stimulates luteinising …

Objective. We aimed to clarify the efficacy of dapagliflozin versus liraglutide in patients with
overweight or obesity and type 2 diabetes mellitus (T2DM) at the beginning of the …

While rapidly emerging evidence suggests that perioperative GLP-1-RAs use is associated
with delayed gastric emptying and increased risk of bronchoaspiration (particularly in …

Purpose The glucagon-like peptide-1 receptor (GLP-1R) is an effective therapeutic target for
type 2 diabetes mellitus (T2DM) and non-alcoholic steatohepatitis (NASH). Research has …